人类呼吸道合胞病毒治疗市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

市场按类型(A 型呼吸道合胞病毒、B 型呼吸道合胞病毒)、治疗类型(支持性护理、医院护理)、管理途径和地理位置细分。

市场快照

human respiratory syncytial virus treatment market
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 10 %
respiratory syncytial virus diagnostic market growth

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

人类呼吸道合胞病毒治疗市场预计在预测期内的复合年增长率为 10%,这归因于人类呼吸道合胞病毒感染率的增加和技术的进步。人类呼吸道合胞病毒感染肺部并引起慢性呼吸道感染、哮喘和细支气管炎。根据世界卫生组织 (WHO),呼吸道合胞体是一岁以下儿童的第二大死因。此外,2017 年约有 3300 万人经历了严重的呼吸道感染。这可归因于可用于预防或治疗疾病的治疗选择较少,从而促进了人类呼吸道合胞病毒治疗市场的增长。

报告范围

根据范围,人呼吸道合胞病毒也称为人正肺病毒,是一种引起呼吸道感染的合胞病毒。人类呼吸道合胞病毒治疗市场按类型、给药途径治疗类型和地理细分。

By Type
Type A Respiratory Syncytial Virus
Type B Respiratory Syncytial Virus
By Route of Administration
Oral
Parenteral
By Treatment Type
Supportive Care
Hospital Care
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

以人呼吸道合胞病毒治疗市场为基础,支持性护理未来有望健康成长

支持性护理有望在未来见证健康增长。支持治疗是第一线治疗。对乙酰氨基酚等非处方药用于治疗患者。全球人类呼吸道合胞病毒 (RSV) 的日益流行正在促进该细分市场的增长。支持性护理中 RSV 的治疗包括氧气和液体管理,其中鼻吸和润滑用于鼻塞退烧药用于发烧。由于这种疾病在两岁儿童中非常常见,支持性护理是呼吸道合胞病毒的主要治疗方法,这导致了该段的增长。

 rsv diagnostics market size

北美预计将在市场上占有最大份额,预计在预测期内也将如此

北美处于该地区增长的最前沿,也是全球舞台上重要的收入贡献者。随着该地区婴儿病毒感染发病率的增加,患者数量的增加正在刺激该地区的发展。根据美国国家过敏和传染病研究所 (NIAID) 的数据,大多数儿童在 2 岁时感染呼吸道合胞病毒,其中每年有 75000 至 125000 人住院。此外,预计增加医疗保健支出和完善的医疗保健基础设施将促进北美的收入增长。

rsv diagnostics market

竞争格局

人类呼吸道合胞病毒治疗市场分散竞争,由几个主要参与者组成。目前主导市场的一些公司是阿斯利康、F. Hoffmann-La Roche Ltd、AbbVie Inc、ReViral Ltd.、Aurobindo Pharma、Zydus Pharmaceuticals、Merck & Co 和 Bausch Health。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increased Prevalence of Respiratory Syncytial Virus

      2. 4.2.2 Advances in Technologies

    3. 4.3 Market Restraints

      1. 4.3.1 Less Availability of Safe and Effective Antiviral Drugs

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Type

      1. 5.1.1 Type A Respiratory Syncytial Virus

      2. 5.1.2 Type B Respiratory Syncytial Virus

    2. 5.2 By Route of Administration

      1. 5.2.1 Oral

      2. 5.2.2 Parenteral

    3. 5.3 By Treatment Type

      1. 5.3.1 Supportive Care

      2. 5.3.2 Hospital Care

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AstraZeneca

      2. 6.1.2 F. Hoffmann-La Roche Ltd

      3. 6.1.3 AbbVie Inc

      4. 6.1.4 ReViral Ltd.

      5. 6.1.5 Aurobindo Pharma

      6. 6.1.6 Zydus Pharmaceuticals

      7. 6.1.7 Merck & Co

      8. 6.1.8 Bausch Health

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The undefined market is studied from 2018 - 2026.

The undefined is growing at a CAGR of 10% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

AbbVie Inc, F. Hoffmann-La Roche Ltd, Aurobindo Pharma, Zydus Pharmaceuticals, Merck & Co are the major companies operating in undefined.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!